Alvimopan Patent Expiration
Alvimopan is Used for accelerating gastrointestinal recovery following bowel resection surgeries. It was first introduced by Cubist Pharmaceuticals Inc
Alvimopan Patents
Given below is the list of patents protecting Alvimopan, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Entereg | US5250542 | Peripherally selective piperidine carboxylate opioid antagonists |
Mar 29, 2016
(Expired) | Cubist Pharms |
| Entereg | US5434171 | Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates |
Dec 08, 2013
(Expired) | Cubist Pharms |
| Entereg | US6469030 | Methods for the treatment and prevention of ileus |
Nov 29, 2020
(Expired) | Cubist Pharms |
| Entereg | US8112290 | Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug | Jul 31, 2030 | Cubist Pharms |
| Entereg | US8645160 | Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug | Jun 18, 2029 | Cubist Pharms |
| Entereg | US8946262 | Methods of preventing and treating gastrointestinal dysfunction | Feb 12, 2030 | Cubist Pharms |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Alvimopan Generics
Several generic applications have been filed for Alvimopan. The first generic version for Alvimopan was by Watson Laboratories Inc An Indirect Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc and was approved on Dec 19, 2019. And the latest generic version is by Hikma Pharmaceuticals Usa Inc and was approved on Aug 31, 2023.
Given below is the list of companies who have filed for Alvimopan generic.
1. HIKMA
Hikma Pharmaceuticals Usa Inc has filed for 1 generic for Alvimopan. Given below are the details of the strengths of this generic introduced by Hikma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 12MG | capsule | Prescription | ORAL | AB | Aug 31, 2023 |
2. ENDO OPERATIONS
Endo Operations Ltd has filed for 1 generic for Alvimopan. Given below are the details of the strengths of this generic introduced by Endo Operations.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 12MG | capsule | Prescription | ORAL | AB | Jan 24, 2023 |
3. WATSON LABS TEVA
Watson Laboratories Inc An Indirect Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc has filed for 1 generic for Alvimopan. Given below are the details of the strengths of this generic introduced by Watson Labs Teva.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 12MG
(reference standard) | capsule | Prescription | ORAL | AB | Dec 19, 2019 |